Zollinger‑Ellison syndrome-associated gastric outlet obstruction - Symptoms, Causes, Treatment & Prevention

```html

Overview

Zollinger‑Ellison syndrome (ZES) is a rare condition in which one or more gastrin‑producing tumors (gastrinomas) develop, most often in the duodenum or pancreas. The excess gastrin drives the stomach to produce massive amounts of gastric acid. When this acid overwhelms the protective mechanisms of the upper gastrointestinal (GI) tract, it can cause peptic ulcers, diarrhea, and—in some patients—**gastric outlet obstruction (GOO)**, a blockage that prevents food from passing from the stomach into the duodenum.

• Prevalence of ZES: Approximately 0.1 – 0.3 cases per 100,000 people worldwide (Mayo Clinic, 2023).
• Prevalence of GOO in ZES: Up to 25 % of patients with untreated or poorly controlled ZES develop GOO due to ulcer scarring, edema, or tumor infiltration (Cleveland Clinic, 2022).
• Typical age: Most diagnoses occur between 30 and 60 years, but children and older adults can be affected.
• Sex distribution: Slight male predominance (≈55 % male).

The combination of ZES and GOO is a medical emergency because the obstruction can cause severe vomiting, dehydration, electrolyte imbalance, and malnutrition. Early recognition and a coordinated approach involving gastroenterology, surgery, and endocrinology are essential.

Symptoms

Symptoms arise from two overlapping processes: hyperacidic damage (ulcers, reflux) and mechanical blockage of the pyloric outlet.

Symptoms related to excess gastric acid

• Recurrent abdominal pain: Often described as burning or gnawing; may improve with antacids but returns quickly.
• Frequent duodenal or gastric ulcers: May cause perforation or bleeding.
• Diarrhea: Acid inactivates pancreatic enzymes and damages intestinal mucosa, leading to watery stools (often 4–6 times/day).
• Heartburn / gastro‑esophageal reflux disease (GERD): Persistent acid reflux.
• Weight loss: Due to malabsorption and reduced oral intake.

Symptoms specifically linked to gastric outlet obstruction

• Early‑satiety and bloating: Feeling full after a few bites.
• Persistent nausea and non‑bloody vomiting: Vomitus may be undigested food or “coffee‑ground” material if there is concurrent ulcer bleeding.
• Visible peristaltic waves: Undulating movements across the abdomen as the stomach tries to force contents past the blockage.
• Dehydration signs: Dry mouth, decreased urine output, dizziness.
• Electrolyte disturbances: Low potassium (hypokalemia) or metabolic alkalosis from vomiting.
• Jaundice or weight loss (late stage): If a tumor directly compresses the biliary tree.

Causes and Risk Factors

Underlying cause

ZES is caused by gastrin‑secreting neuroendocrine tumors (gastrinomas). In about 25 % of cases the tumors are part of the hereditary condition multiple endocrine neoplasia type 1 (MEN‑1). The excess gastrin induces parietal cell hyperactivity, leading to hyperchlorhydria.

How GOO develops in ZES

• Peptic ulcer scarring: Repeated duodenal ulceration heals with fibrotic tissue that narrows the pyloric channel.
• Edematous mucosa: Acute inflamed ulcer edges swell enough to block the outlet.
• Direct tumor invasion: Large gastrinomas, especially pancreatic head lesions, can compress the duodenum.
• Secondary malignancy: Rarely, gastrinomas become malignant and infiltrate surrounding structures.

Risk factors

• Family history of MEN‑1 or other endocrine neoplasias.
• Known gastrinoma (diagnosed via imaging or endoscopy).
• Long‑standing untreated ZES leading to chronic ulcer disease.
• Smoking and heavy alcohol use (exacerbate ulcer formation).
• Helicobacter pylori infection – although not a direct cause of ZES, it can worsen ulcer burden.

Diagnosis

Because the presentation can mimic peptic ulcer disease or simple GOO, a systematic work‑up is required.

Laboratory tests

• Fasting serum gastrin: Levels > 1,000 pg/mL (normal < 100 pg/mL) strongly suggest ZES, especially after a secretin stimulation test.
• Secretin stimulation test: Paradoxical rise in gastrin after IV secretin confirms gastrinoma.
• Electrolytes & renal function: Assess dehydration, hypokalemia, and metabolic alkalosis.
• Stool occult blood: Detects occult GI bleeding.

Imaging studies

• Upper endoscopy (EGD): Direct visualization of ulcers, edema, and the obstruction; allows biopsy to rule out malignancy.
• Endoscopic ultrasound (EUS): Sensitive for small gastrinomas (< 1 cm) and for assessing depth of tumor invasion.
• CT or MRI abdomen: Staging to locate primary tumor and liver metastases.
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT: Detects neuroendocrine tumor sites with high specificity.

Functional tests for obstruction

• Upper GI series (barium study): Shows delayed gastric emptying, “string sign” of the pylorus, or a “shoulder” indicating ulcer stricture.
• Gastric emptying scintigraphy: Quantifies the degree of obstruction when endoscopic findings are equivocal.

Diagnostic criteria (summary)

1. Fasting gastrin > 1,000 pg/mL OR positive secretin stimulation test.
2. Radiologic or endoscopic evidence of a gastrinoma.
3. Endoscopic or radiographic proof of gastric outlet obstruction (stenosis, ulcer scar, tumor compression).

Treatment Options

Treatment must address both the hormone‑driven acid hypersecretion and the mechanical blockage.

Medical management of acid hypersecretion

• Proton pump inhibitors (PPIs): High‑dose omeprazole 80 mg daily or equivalent (e.g., esomeprazole 40 mg BID). PPIs control acid output in > 90 % of patients (Mayo Clinic, 2023).
• Histamine‑2 receptor antagonists (H2RAs): Used adjunctively if PPI tolerance wanes.
• Octreotide or lanreotide (somatostatin analogues): Reduce gastrin secretion; useful when tumors are unresectable or cause refractory symptoms.
• Proton‑pump‑inhibitor “stress‑dose” therapy: During peri‑operative periods to prevent ulcer recurrence.

Definitive treatment of gastrinomas

1. Surgical resection: Preferred for localized tumors. Enucleation or pancreatoduodenectomy (Whipple) may be required for pancreatic head lesions.
2. Endoscopic tumor ablation: Radiofrequency or cryotherapy for small duodenal gastrinomas when surgery carries high risk.
3. Targeted systemic therapy: Everolimus or sunitinib for metastatic disease (NIH, 2022).
4. Peptide receptor radionuclide therapy (PRRT): 177Lu‑DOTATATE for somatostatin‑receptor positive tumors.

Management of gastric outlet obstruction

• Endoscopic balloon dilation: First‑line for short (< 2 cm) ulcer strictures; success rates 70‑80 %.
• Self‑expanding metal stent (SEMS): Palliative option for malignant or refractory obstruction.
• Surgical bypass: Gastrojejunostomy (Billroth II) or duodenal ulcer excision when endoscopic therapy fails or when tumor infiltration mandates resection.
• Nasogastric decompression: Short‑term relief of vomiting while definitive therapy is arranged.

Lifestyle and supportive measures

• Small, low‑fat, low‑acid meals (avoid citrus, tomato, coffee, chocolate).
• Fluid replacement with oral rehydration solutions; intravenous fluids for severe dehydration.
• Electrolyte monitoring—especially potassium and magnesium.
• Smoking cessation and limiting alcohol intake.
• Vaccination against hepatitis B and regular liver imaging if metastatic disease is present.

Living with Zollinger‑Ellison Syndrome‑Associated Gastric Outlet Obstruction

Daily management tips

• Medication adherence: Take PPIs exactly as prescribed—usually 30 minutes before breakfast and dinner. Use a medication tracker or smartphone reminder.
• Meal planning: Eat 5–6 small meals per day; chew food thoroughly to reduce gastric workload.
• Hydration strategy: Sip water between bites; avoid large fluid intake with meals to prevent gastric distension.
• Weight monitoring: Record weekly weight; a loss > 5 % in a month warrants medical review.
• Symptom diary: Note frequency of vomiting, pain intensity, stool consistency, and any new medication side effects.
• Regular follow‑up: Every 3–6 months with gastroenterology and endocrinology; more frequent if tumor burden changes.

Psychosocial considerations

Living with a chronic, rare disease can be stressful. Connect with patient support groups (e.g., Neuroendocrine Tumor Research Foundation) and consider counseling to address anxiety or depression related to dietary restrictions and frequent medical appointments.

Prevention

Because the primary cause (gastrinoma) cannot be prevented, the focus is on reducing complications:

• Early detection of gastrinomas in at‑risk families (MEN‑1 screening with genetic counseling).
• Prompt treatment of H. pylori infection to lower ulcer burden.
• Adherence to high‑dose PPI therapy to keep gastric pH > 4, which markedly reduces ulcer formation.
• Regular endoscopic surveillance (every 1–2 years) for patients with known gastrinomas, especially if prior ulcers were present.

Complications

If untreated or poorly controlled, ZES‑related GOO can lead to:

• Severe malnutrition: Resulting from chronic vomiting and poor oral intake.
• Electrolyte imbalance: Hypokalemia, hyponatremia, and metabolic alkalosis, which can precipitate cardiac arrhythmias.
• Peptic ulcer perforation: Life‑threatening intra‑abdominal infection.
• Upper GI bleeding: From eroded ulcers; may require endoscopic hemostasis or transfusion.
• Refractory GOO: Necessitating surgical bypass.
• Metastatic gastrinoma: Liver, lymph node, or bone spread carries a 5‑year survival of approximately 58 % (NIH, 2022).

When to Seek Emergency Care

---

Sources: Mayo Clinic, Cleveland Clinic, National Institutes of Health (NIH), World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and peer‑reviewed journals (e.g., Journal of Clinical Endocrinology & Metabolism, 2022; Gastroenterology, 2021).

```